Consequences of Recurrent Hyperkalemia on Cardiovascular Outcomes and Mortality
Main finding · All-cause mortalityResult — go to the resultHazard ratio 1.29 95% CI 1.20–1.38Authors' conclusion
In patients with CKD, recurrent HK increased the risks of all-cause mortality, MACE+, and hospitalized arrhythmia compared with normokalemia, including in a subset of patients with HF.
Study context
- Population
- Adults with stage 3/4 chronic kidney disease (CKD), with or without heart failure (HF), Optum Market Clarity database (January 2016 to August 2022)6,337 matched pairs
- Exposure
- Recurrent hyperkalemia vs normokalemia
- Outcome
- All-cause mortality
Methodological detailsexactly and propensity score-matched
- Exactly and propensity score-matched
Main finding
As reported in the abstract
Hazard ratio
1.29
95% CI 1.20–1.38
Recurrent HKvs Normokalemia
HR 1.29 (95% CI 1.20–1.38)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | |
|---|---|---|
| All-cause mortality, HF substudy (subgroup)HF substudy (2,129 matched pairs) | 1.30 (1.18–1.44) | |
| MACE+ (all-cause mortality or hospitalized MI, stroke or HF)Recurrent HKvs NormokalemiaOverall | 1.53 (1.43–1.65) | |
| MACE+ (all-cause mortality or hospitalized MI, stroke or HF)Recurrent HKvs NormokalemiaHF substudy | 1.45 (1.29–1.64) | |
| Hospitalized arrhythmiaRecurrent HKvs NormokalemiaOverall | 1.94 (1.74–2.16) | |
| Hospitalized arrhythmiaRecurrent HKvs NormokalemiaHF substudy | 1.85 (1.55–2.21) | |
| 0.512Hazard ratio (log scale) |
Original publication
Consequences of Recurrent Hyperkalemia on Cardiovascular Outcomes and Mortality. JACC Adv. Published 14 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →